Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | MPI | P34949 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30388663 | 1.00 | KDM4E (0.72) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL30880425 | 0.86 | KDM4E (0.72) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL27218343 | 0.86 | KDM4E (0.72) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| Imidazole SCHEMBL28276515 | 0.85 | KDM4E (0.54) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL29415434 | 0.84 | KDM4E (1.00) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL2805779 | 0.84 | KDM4E (1.00) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL28579900 | 0.82 | KDM4E (0.53) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL28581895 | 0.81 | KDM4E (0.49) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL3985154 | 0.81 | KDM4E (0.74) | KDM4ETDP1MEN1KMT2AALDH1A1 | |
| SCHEMBL1620204 | 0.79 | KDM4E (0.72) | KDM4ETDP1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | claimed |
| CN-109761998-B | Preparation and application of bis-fluoroquinolone thiadiazole urea Fleroxacin derivative | 河南大学 | 2023-06-02 | — | — | CN | claimed |
| CN-109761997-B | Preparation and application of bis-fluoroquinolone thiadiazole urea N-methyl lomefloxacin derivative | 河南大学 | 2023-05-02 | — | — | CN | claimed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| CN-109438472-B | Bis-fluoroquinolone oxadiazole urea derivative containing N-methyl gatifloxacin and preparation method and application thereof | 郑州工业应用技术学院 | 2021-07-20 | — | — | CN | claimed |
| CN-109369675-B | Bis-fluoroquinolone oxadiazole urea pefloxacin derivative and preparation method and application thereof | 郑州工业应用技术学院 | 2021-07-06 | — | — | CN | claimed |
| CN-109400627-B | Bis-fluoroquinolone oxadiazole urea derivative containing N-methyl lomefloxacin and preparation method and application thereof | 郑州工业应用技术学院 | 2021-07-06 | — | — | CN | claimed |
| CN-109369677-B | Bis-fluoroquinolone oxadiazole urea N-methyl ciprofloxacin derivative and preparation method and application thereof | 郑州工业应用技术学院 | 2021-07-06 | — | — | CN | claimed |
| CN-109438481-B | Bis-fluoroquinolone oxadiazole urea derivative containing N-methylmoxifloxacin and preparation method and application thereof | 郑州工业应用技术学院 | 2021-07-06 | — | — | CN | claimed |
| CN-109400632-B | Bis-fluoroquinolone oxadiazole urea derivative containing N-methylenoxacin and preparation method and application thereof | 郑州工业应用技术学院 | 2021-07-06 | — | — | CN | claimed |
| EP-2074111-A2 | QUINOLONE CARBOXYLIC ACIDS, DERIVATIVES THEREOF, PROCESSES FOR ITS PREPARATION AND ITS USE AS ANTIBACTERIAL AGENTS | Bausch & Lomb Incorporated (US) | 2009-07-01 | — | — | EP | claimed |
| CN-101420956-A | Fluoroquinolone carboxylic acid salt compositions | IDEXX LAB INC (US) | 2009-04-29 | — | — | CN | claimed |
| WO-2008091752-A2 | QUINOLONE CARBOXYLIC ACIDS, DERIVATIVES THEREOF, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL AGENTS | BAUSCH & LOMB INCORPORATED (US) | 2008-07-31 | — | — | WO | claimed |
| US-20080176834-A1 | Quinolone Carboxylic Acids, Derivatives Thereof, and Methods of Making and Using Same | PRECISION DERMATOLOGY, INC. | 2008-07-24 | — | — | US | claimed |
| WO-2008045673-A2 | QUINOLONE CARBOXYLIC ACIDS, DERIVATIVES THEREOF, PROCESSES FOR ITS PREPARATION AND ITS USE AS ANTIBACTERIAL AGENTS | BAUSCH & LOMB INCORPORATED (US) | 2008-04-17 | — | — | WO | claimed |
| CN-1235881-C | Improved process for preparing fluoroquinolone carboxylic acids | BAYER (DE) | 2006-01-11 | — | — | CN | claimed |
| EP-1236718-B1 | Improved process for the preparation of fluoro-quinolonecarboxylic acids | BAYER CHEMICALS AG (DE) | 2004-08-11 | — | — | EP | claimed |
| US-6590101-B2 | Hydrolysis of the corresponding C1-C4-alkyl esters with addition of water, acetic acid, and sulfuric acid using a drastically reduced amount of sulfuric acid | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | claimed |
| CN-1371904-A | Improved process for preparing fluoroquinolone carboxylic acids | BAYER (DE) | 2002-10-02 | — | — | CN | claimed |
| US-20020120138-A1 | Process for the preparation of fluoroquinolonecarboxylic acids | LANXESS DEUTSCHLAND GMBH (DE) | 2002-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | KDM4E 4061/4885TDP1 100/4885MEN1 1972/4885 |
| US-20020120138-A1 | Process for the preparation of fluoroquinolonecarboxylic acids | ADH1C, CTRC, ADH1A | KDM4E 2934/4885TDP1 1931/4885MEN1 4274/4885 |
| US-20080176834-A1 | Quinolone Carboxylic Acids, Derivatives Thereof, and Methods of Making and Using Same | NQO2, QARS1, QPCT | KDM4E 1611/4885TDP1 2620/4885MEN1 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.